Weekly roundup: Science, strategy, and shifting policy
The winds they are a-changin’, with the tail-end of Hurricane Erin bringing what feels like an abrupt end to summer here in northern Europe. And what will the new season bring to the world of biotech and pharma? Only time will tell. Optimum’s clients are certainly gearing up though – and we can all expect September to get pretty busy pretty quickly. Ahead of that, we have a couple of curtain-raiser news items, as below.
Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper
Resolution Therapeutics, a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies to treat inflammatory and fibrotic diseases, will host a virtual R&D webinar on Wednesday 17th September 2025 at 2pm BST / 9am ET / 6am PT for investors, analysts and media. To register, please use this link.
Leucid Bio to participate in the 23rd annual Morgan Stanley Global Healthcare Conference
Leucid Bio, a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the company’s proprietary lateral CAR platform, will attend the 23rd annual Morgan Stanley Global Healthcare Conference in New York. Filippo Petti, Chief Executive Officer, will participate in a fireside chat at 1:05 p.m. ET on Monday, September 8, 2025.
🔥Hot topic
The US Department of Health and Human Services’ decision to cut funding for research into mRNA-based vaccines worth $500 has (unsurprisingly) proved highly controversial. So, what exactly is going to be affected? We break it down in our full article here ⬇️
👥Industry events
Optimum’s 17th Annual Healthcare Conference
Returning to The King’s Fund this autumn, this prestigious invitation-only event brings together investors and executives from across the life sciences sector.
This year is one of relentless disruption and uncertainty as our industry grapples with US health policy and its potential impact on the sector. How can companies with great science get the capital they need to develop the drugs required to fill the looming patent cliff, which Pharma is facing in 2025 and onwards? This is just a taster of what our fantastic line-up of speakers will be sharing their valuable insights about. Register your interest in attending today.
📍Thursday 9th October, London
Sector moves
Keep up to date with the latest industry moves here.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
